Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’

In a recent issue of the <i>American Journal of Cardiovascular Drugs</i>, Thomas et al. analyzed the cardiovascular safety of cyclo-oxygenase (COX)-2 inhibitors (coxibs). In the Recommendations section of the paper, the authors stated that, based on the results of the PRECISION (Prospect...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Urtasun, Martin A., Prozzi, Guillermo Rafael, Marín, Gustavo Horacio, Buschiazzo, Héctor Omar, Cañás, Martín, Dorati, Cristian Matías, Mordujovich, Perla
Formato: Articulo Contribucion a revista
Lenguaje:Inglés
Publicado: 2017
Materias:
Ciencias Médicas
Cardiovascular safety
Celecoxib
Farmacología
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/104914
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-104914
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
Cardiovascular safety
Celecoxib
Farmacología
spellingShingle Ciencias Médicas
Cardiovascular safety
Celecoxib
Farmacología
Urtasun, Martin A.
Prozzi, Guillermo Rafael
Marín, Gustavo Horacio
Buschiazzo, Héctor Omar
Cañás, Martín
Dorati, Cristian Matías
Mordujovich, Perla
Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’
topic_facet Ciencias Médicas
Cardiovascular safety
Celecoxib
Farmacología
description In a recent issue of the <i>American Journal of Cardiovascular Drugs</i>, Thomas et al. analyzed the cardiovascular safety of cyclo-oxygenase (COX)-2 inhibitors (coxibs). In the Recommendations section of the paper, the authors stated that, based on the results of the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen) trial, celecoxib at moderate doses is not inferior to ibuprofen or naproxen in terms of cardiovascular safety. The PRECISION investigators seem to imply that celecoxib is a ‘cardiovascular safe’ drug, and we would like to challenge this statement with a more detailed analysis of the PRECISION trial.
format Articulo
Contribucion a revista
author Urtasun, Martin A.
Prozzi, Guillermo Rafael
Marín, Gustavo Horacio
Buschiazzo, Héctor Omar
Cañás, Martín
Dorati, Cristian Matías
Mordujovich, Perla
author_facet Urtasun, Martin A.
Prozzi, Guillermo Rafael
Marín, Gustavo Horacio
Buschiazzo, Héctor Omar
Cañás, Martín
Dorati, Cristian Matías
Mordujovich, Perla
author_sort Urtasun, Martin A.
title Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’
title_short Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’
title_full Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’
title_fullStr Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’
title_full_unstemmed Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’
title_sort comment on ‘‘coxibs refocus attention on the cardiovascular risks of non-aspirin nsaids’’
publishDate 2017
url http://sedici.unlp.edu.ar/handle/10915/104914
work_keys_str_mv AT urtasunmartina commentoncoxibsrefocusattentiononthecardiovascularrisksofnonaspirinnsaids
AT prozziguillermorafael commentoncoxibsrefocusattentiononthecardiovascularrisksofnonaspirinnsaids
AT maringustavohoracio commentoncoxibsrefocusattentiononthecardiovascularrisksofnonaspirinnsaids
AT buschiazzohectoromar commentoncoxibsrefocusattentiononthecardiovascularrisksofnonaspirinnsaids
AT canasmartin commentoncoxibsrefocusattentiononthecardiovascularrisksofnonaspirinnsaids
AT doraticristianmatias commentoncoxibsrefocusattentiononthecardiovascularrisksofnonaspirinnsaids
AT mordujovichperla commentoncoxibsrefocusattentiononthecardiovascularrisksofnonaspirinnsaids
bdutipo_str Repositorios
_version_ 1764820442609090564

Ejemplares similares